NYKD — Nykode Therapeutics ASA Share Price
0.000.00%
Last trade - 00:00- NOK4.23bn
- NOK2.51bn
- $12.90m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.25 | ||
| Price to Tang. Book | 2.25 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 29.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -30.96% | ||
| Return on Equity | -21.42% | ||
| Operating Margin | -450.18% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 215 | 33.96 | 7.17 | 12.9 | 15.74 | 13.77 | 282.17% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
Directors
- Tom Pike CHM (57)
- Ole Brekke CEO
- Harald Gurvin CFO (47)
- Agnete Fredriksen EXO
- Ingrid Alfheim DRC (69)
- Erlend Skagseth DRC
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 13th, 2007
- Public Since
- January 27th, 2020
- No. of Employees
- 168
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Oslo Stock Exchange
- Shares in Issue
- 326,546,444
- Address
- Oslo Science Park, Gaustadalleen 21, OSLO, 0349
- Web
- https://nykode.com/
- Phone
- +47 22958193
- Auditors
- Deloitte AS
Upcoming Events for NYKD
Q1 2024 Nykode Therapeutics ASA Earnings Release
Nykode Therapeutics ASA Annual Shareholders Meeting
Q2 2024 Nykode Therapeutics ASA Earnings Release
Similar to NYKD
Arcticzymes Technologies ASA
Oslo Stock Exchange
Bergenbio ASA
Oslo Stock Exchange
Circio Holding ASA
Oslo Stock Exchange
Exact Therapeutics AS
Oslo Stock Exchange
Lifecare AS
Oslo Stock Exchange
FAQ
What is the Nykode Therapeutics ASA share price?
As of Today at 19:16 UTC, shares in Nykode Therapeutics ASA are trading at NOK12.96. This share price information is delayed by 15 minutes.
How has the Nykode Therapeutics ASA share price performed this year?
Shares in Nykode Therapeutics ASA last closed at NOK12.96 and the price had moved by -51.52% over the past 365 days. In terms of relative price strength the Nykode Therapeutics ASA share price has underperformed the FTSE Global All Cap Index by -54.49% over the past year.
What are the analyst and broker recommendations for Nykode Therapeutics ASA?
The overall consensus recommendation for Nykode Therapeutics ASA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Nykode Therapeutics ASA dividend yield?
Nykode Therapeutics ASA does not currently pay a dividend.
Does Nykode Therapeutics ASA pay a dividend?
Nykode Therapeutics ASA does not currently pay a dividend.
When does Nykode Therapeutics ASA next pay dividends?
Nykode Therapeutics ASA does not currently pay a dividend.
How do I buy Nykode Therapeutics ASA shares?
To buy shares in Nykode Therapeutics ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nykode Therapeutics ASA?
As of the previous close price of NOK12.96, shares in Nykode Therapeutics ASA had a market capitalisation of NOK4.23bn.
Where are Nykode Therapeutics ASA shares listed?
Here are the trading details for Nykode Therapeutics ASA:
- Country of listing: Norway
- Exchange: OSL
- Ticker Symbol: NYKD
What kind of share is Nykode Therapeutics ASA?
Based on an overall assessment of its quality, value and momentum Nykode Therapeutics ASA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nykode Therapeutics ASA share price forecast for 2024?
The analyst consensus target price for shares in Nykode Therapeutics ASA is NOK39.21. That is 202.55% above the last closing price of NOK12.96.
Analysts covering Nykode Therapeutics ASA currently have a consensus Earnings Per Share (EPS) forecast of -$0.17 for the next financial year.
What is the trend in the Nykode Therapeutics ASA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nykode Therapeutics ASA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -43.38%.
As of the last closing price of NOK12.96, shares in Nykode Therapeutics ASA were trading -37.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nykode Therapeutics ASA PE Ratio?
The Nykode Therapeutics ASA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at NOK12.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nykode Therapeutics ASA?
Nykode Therapeutics ASA's management team is headed by:
- Tom Pike - CHM
- Ole Brekke - CEO
- Harald Gurvin - CFO
- Agnete Fredriksen - EXO
- Ingrid Alfheim - DRC
- Erlend Skagseth - DRC